FDA 21 CFR Part 11 & EU Annex 11 Compliance

Compliance with FDA 21 CFR 11 Electronic Records; Electronic Signature and EU Annex 11 Computerised Systems is a must for the pharmaceutical, biotech, medical device, and clinical research industries.

Part 11 and Annex 11 Gap Assessments

ProPharma’s consultants have many years of industry experience implementing Part 11 and Annex 11. They leverage this experience to provide your organization with the benefits of a Part 11 or Annex 11 Gap Assessment, including:

Calendar icon

Time to proactively remediate any critical deficiencies before an audit, rather than having them discovered by a regulator or customer

Spinning cog icon

Insight to focus audit preparation activities on only those areas that need attention.

Signal management icon

Confidence in the success of the next audit or inspection of your systems.

Gradient Image

Part 11 & Annex 11 Compliance Experts

ProPharma’s Part 11 and Annex 11 experts follow risk-based GxP principles to prioritize the processes and systems to assess. They know which areas auditors are most likely to target and apply the following approach to assessing your systems and software validation procedures.

Part 11 & Annex 11 Compliance Assessment Approach

Partner icon

Meet with you to discuss your industry, your products, and your markets to determine the exact section of Part 11 and Annex 11 with which you need to comply.

Meet with you to discuss your industry, your products, and your markets to determine the exact section of Part 11 and Annex 11 with which you need to comply.

Read Less
Webinar icon

Discuss any specific areas of concern. For example, you might feel confident about your software quality policies, but are uncertain whether or not your validation documentation will withstand...

Read More

Discuss any specific areas of concern. For example, you might feel confident about your software quality policies, but are uncertain whether or not your validation documentation will withstand serious scrutiny.

Read Less
Checkmark icon

Tailor ProPharma’s standard 200+ question Part 11 and Annex 11 assessment checklist to place the focus on the areas that are most important to your organization.

Tailor ProPharma’s standard 200+ question Part 11 and Annex 11 assessment checklist to place the focus on the areas that are most important to your organization.

Read Less
Quality & Compliance icon

Conduct the Assessment in a manner similar to a regulator or potential customer. We ask the same tough questions, inspect your evidence, and challenge your practices.

Conduct the Assessment in a manner similar to a regulator or potential customer. We ask the same tough questions, inspect your evidence, and challenge your practices.

Read Less
Document search icon

Provide a Part 11 and Annex 11 Assessment Report with ratings for each question. Areas of non-compliance will be categorized as either “critical”, “major”, or “minor” in alignment with a risk-based...

Read More

Provide a Part 11 and Annex 11 Assessment Report with ratings for each question. Areas of non-compliance will be categorized as either “critical”, “major”, or “minor” in alignment with a risk-based compliance program.

Read Less
Message received icon

Deliver a Compliance Action Plan with a list of specific, prioritized activities to complete to achieve Part 11 and Annex 11 compliance.

Deliver a Compliance Action Plan with a list of specific, prioritized activities to complete to achieve Part 11 and Annex 11 compliance.

Read Less
Service icon

Host follow-up meetings to ensure that you understand the Part 11 and Annex 11 assessment results and recommended remediation activities.

Host follow-up meetings to ensure that you understand the Part 11 and Annex 11 assessment results and recommended remediation activities.

Read Less

Part 11 and Annex 11 Compliance Services

Computer System Validation icon

Computer System Compliance

Computer System Compliance

Compliance

IT Process Compliance

IT Process Compliance

Submissions icon

Validation Compliance

Validation Compliance

Computer System Compliance

Part 11 and Annex 11 contain very specific functional requirements for regulated systems. ProPharma’s consultants work with your technical experts to determine the specific system configurations needed for compliance. When systems require customization, they review the designs to ensure that the end-result will be compliant from the first release.

Person holding stethoscope and mobile phone in front of laptop

IT Process Compliance

Regulations require procedures and controls for GxP systems, such as back-up, disaster recovery, security, access management, risk assessment and management, change control, validation, issue management, and record retention. ProPharma’s consultants not only develop the Standard Operating Procedures (SOPs) to meet regulatory requirements and incorporate industry-standard practices, but also ensure that the SOPs are tailored to your organization’s roles and responsibilities, technologies, and QMS infrastructure.

Two engineers reviewing a small computer device in front of two computer monitors

Validation Compliance

Computer System Validation? Computer Software Assurance? ProPharma has the experts to work with you to develop a risk-based methodology whether it’s your organization’s first validation project or you need to bring an older validation package into compliance with modern standards.

Hand holding pen between fingers typing on laptop and using tablet device
Validation Center Logo

Part 11 and Annex 11 Training & Resources

Access essential training and resources for Part 11 and Annex 11 at Validation Center, ProPharma knowledge center and resource.

Attend free webinars, enroll in online and in-person classes in the US and Europe, and download valuable templates and standard operating procedures. Validation Center offers everything you need for Part 11, Annex 11, and other validation and compliance training and resources.

Optimize Compliance with Part 11 and Annex 11 Expertise

Unlock the full potential of your compliance strategy with our expert guidance on FDA 21 CFR Part 11 and EU Annex 11. Ensure your systems meet the highest standards of data integrity and regulatory compliance by partnering with us today.

News & Insights

The Strategic Importance of a Consumer Health Service Line

April 27, 2026

The Strategic Importance of a Consumer Health Service Line

Explore how Consumer Health brands can enhance consumer engagement through proactive service strategies, ensuring safety, compliance, and brand loyalty in a complex market.

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI Use in Manufacturing

April 22, 2026

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI ...

The FDA's warning letter to Purolea Cosmetics Lab highlights the need for rigorous AI governance in pharmaceutical manufacturing. Compliance is crucial for product quality and safety.

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Global Market Reach

April 20, 2026

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Gl...

Explore the benefits of offshoring medical information services, enhancing global support and operational flexibility for healthcare and pharmaceutical companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Case Study How a Novel Real World Evidence Strategy Helped Bring a Class III Device to Market - ProPharma

March 23, 2026

Real World Evidence for Class III Devices: A Smarter Path to PMA

Struggling to generate clinical evidence for Class III devices without costly, multi-year trials? Discover how ProPharma helped an orthopedic device company leverage existing registry data to support...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

The Strategic Importance of a Consumer Health Service Line

April 27, 2026

The Strategic Importance of a Consumer Health Service Line

Explore how Consumer Health brands can enhance consumer engagement through proactive service strategies, ensuring safety, compliance, and brand loyalty in a complex market.

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI Use in Manufacturing

April 22, 2026

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI ...

The FDA's warning letter to Purolea Cosmetics Lab highlights the need for rigorous AI governance in pharmaceutical manufacturing. Compliance is crucial for product quality and safety.

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Global Market Reach

April 20, 2026

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Gl...

Explore the benefits of offshoring medical information services, enhancing global support and operational flexibility for healthcare and pharmaceutical companies.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Case Study How a Novel Real World Evidence Strategy Helped Bring a Class III Device to Market - ProPharma

March 23, 2026

Real World Evidence for Class III Devices: A Smarter Path to PMA

Struggling to generate clinical evidence for Class III devices without costly, multi-year trials? Discover how ProPharma helped an orthopedic device company leverage existing registry data to support...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow